Qilian International Corp (QLI) Market Cap to Earnings

Corporate emblem and logo of Qilian International Holding Group Limited (QLI)

This P/E ratio chart, which currently stands at -24.70, clearly illustrates price changes and allows for a valuation of Qilian International (QLI). Qilian International (QLI) produces chemical extracts and traditional medicines, leveraging state-issued GMP licenses. However, strict PRC oversight and raw material price volatility create financial risks. Furthermore, the firm is fighting for market share in a low-margin segment, trailing behind large state-owned enterprises.

QLI: qlsyy.net P/E Multiple 07/04/2022 - 08/17/2024

Analytical breakdowns for Qilian International

- share price and expert price forecast:
Price Performance Chart Qilian International Holding Group|QLI - Price Target Chart
- market capitalization details:
Market Value Qilian International Corp|QLI - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Price of a Share Qilian International|QLI - Book Capitalization|Market Value to Book Value qlsyy.net|QLI - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Qilian International|QLI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital qlsyy.net|QLI - Company Debts|Debt to Net Assets Qilian International Holding Group|QLI - Company Long-Term Debts|Short-Term Debt Volume Qilian International|Quick Liquidity qlsyy.net
- earnings and valuation multiples information:
QLI - Net Profit|Company Profit Forecast Qilian International|QLI - P/E Multiple|Forward P/E Multiple Qilian International Corp|QLI - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Qilian International Corp|QLI - Operating profit before deduction of amortization|Earnings per share for the trailing year Qilian International|QLI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months qlsyy.net|QLI - Earnings per share growth in current year|Projected earnings per share growth rate for next year Qilian International
- company sales and revenue statistics:
QLI - Company Sales|Company Projected Revenue Volume Qilian International Holding|QLI - P/S Multiple|Market Cap to Future Revenue Ratio Qilian International Holding Group Limited
Comprehensive company analysis:QLI - Qilian International Holding
Original product of Qilian International Corp

The efficiency of Qilian International (QLI) depends directly on PRC government regulation and raw material costs. The ratio of market capitalization to net income, reflected through the company's adjusted P/E, measures the investment payback period. The stability of this trend often masks the internal restructuring of institutional portfolios. Analyzing this momentum during the consolidation phase foreshadows a future price reversal. The final valuation of the asset requires accounting for export demand.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple EPRX|P/E Multiple bioharvest.com (BHST)|Price to Earnings Ratio Invizyne Technologies EXOZ|ORMP: Price to Earnings Multiple|ENTX: Price to Earnings Ratio|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|cumberlandpharma.com (CPIX) - P/E Multiple|QNTM (Quantum BioPharma) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|P/E Multiple Rani Therapeutics Holdings (RANI)|P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Market Cap to Earnings|LEXX - Price to Earnings Ratio|PULM (Pulmatrix) - Price to Earnings Multiple|Pheton Holdings Ltd (PTHL) - Price to Earnings Ratio|Aptorum - Company Value to Net Income|Price to Earnings Ratio LYRA|Price to Earnings Ratio Impact BioMedical Inc (IBO)|P/E Multiple TNFA|YCBD: Market Cap to Net Income|Price to Earnings Ratio PainReform PRFX|altamiratherapeutics.com (CYTO) - Market Cap to Earnings|LIPO: Price to Earnings Ratio|OPTN (optinose.com) - Price to Earnings Multiple|PIRS: P/E Multiple|PROC - Business Payback Period|PTPI (Petros Pharma) - P/E Multiple|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)